While the reasons for this remain unclear, it is interesting to note that the Mezger group likewise described that a CRISPR-Cas9-guided knockout of TIGIT promotes functionality of CAR-bearing NK-92 cell preparations only toward AML (i.e., U937) but not toward B-cell precursor (BCP)-ALL (i.e., Nalm-6) [39]. This evidence concerns the gene TIGIT and acute lymphoblastic leukemia.